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Purpose: To compare the cytotoxic effects of preservative-free azithromycin on corneal 
epithelial cells in vivo with those of preservative-free netilmicin and levofloxacin, and the 
preservative benzalkonium chloride (BAK).
Methods: Rabbit corneal epithelial cells in vitro were incubated for 15 minutes or 6 hours with 
commercially available ophthalmic preservative-free netilmicin 0.3%, levofloxacin 0.3%, or 
azithromycin 1.5% preparations or different concentrations of unpreserved azithromycin and 
different concentrations of BAK. Qualitative analysis was undertaken using phase-contrast optics 
to examine the morphological aspects of cell cultures and quantitative analysis was undertaken 
by measuring the release of the cytoplasmic enzyme lactate dehydrogenase into the medium 
immediately and 24 hours after exposure to drugs. Finally, we observed the wound-healing 
rate of mechanically injured corneal epithelial cells exposed to each antibiotic ophthalmic 
preparation for 48 hours.
Results: Our results show that both the commercially available unpreserved mono-dose 
preparation of azithromycin and ophthalmic preparations of azithromycin up to a concentration 
of 1.5% were virtually devoid of harmful effects under our experimental conditions. This was not 
significantly different from the results obtained for the other antibiotic preparations (P . 0.05) 
tested, but was unlike the results obtained for BAK. Azithromycin 1.5% also showed good 
recovery properties after a mechanical wound test.
Conclusion: Under our experimental conditions, unpreserved azithromycin 1.5% showed a 
much lower toxicity than BAK and did not interfere with the wound-healing process.
Keywords: macrolides, toxicity, corneal epithelial cell culture, wound healing, preservative, 
benzalkonium chloride
Introduction
Azithromycin is an azalide, a second-generation 15-C-atom macrolide antibiotic with 
broad-spectrum activity against Gram-positive, Gram-negative, and atypical bacteria 
such as Chlamydia trachomatis. It shows a potency higher than erythromycin against 
Haemophilus influenzae and Neisseria gonorrhoeae in vitro.1,2
Azithromycin has an intracellular action, as it binds to the bacterial ribosomal 
subunit 50S and inhibits microbial protein synthesis. It is also rapidly distributed in 
the tissue and has good intracellular penetration and transport into phagocytic cells, 
reaching high and sustained levels in tissue – especially at infection sites – including 
in ocular tissue. Thanks to its optimal pharmacokinetic profile, this antibiotic exhibits 
good bacteriostatic and bactericidal time-dependent action and a long post-antibiotic 
effect, thus permitting a short oral or topical 3-day administration regimen.3–7
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In vitro studies have reported that azithromycin has 
anti-inflammatory and immunomodulatory actions in 
addition to its antimicrobial activity, such as the inhibition 
of cytokine and proinflammatory mediator synthesis and 
inflammatory cell migration, and the suppression of the 
nuclear factor kappa B signaling transduction pathway,8–12 
thus providing a rationale for clinical investigation into 
the off-label use of azithromycin eye drops in chronic 
blepharitis.1
Azithromycin 1.5% ophthalmic solution is approved 
in several countries in the European Union for the topical 
treatment of purulent bacterial conjunctivitis caused by 
susceptible strains and of trachomatous conjunctivitis 
caused by Chlamydia trachomatis.1,13–16 Azithromycin 
1.5% ophthalmic solution proved effective and was well 
tolerated in patients with these infections.14,15 Two well-
designed studies showed that in terms of clinical cure rates, 
treatment with azithromycin 1.5% ophthalmic solution for 
3 days was non-inferior to treatment with tobramycin 0.3% 
ophthalmic solution for 7 days in pediatric and adult patients 
with purulent bacterial conjunctivitis and non-inferior to 
a single dose of azithromycin oral suspension in pediatric 
patients with trachomatous conjunctivitis.14,15 Moreover, an 
azithromycin 1.5% ophthalmic solution treatment regimen 
is shorter and has less frequent dosing requirements than 
a tobramycin treatment regimen (potentially improving 
compliance), and has been associated with quicker resolution 
of clinical signs of bacterial conjunctivitis.14,15
The most common adverse events listed in the summary 
of product characteristics as occurring during clinical trials 
and from post-marketing safety data are related to ocular 
discomfort (ie, pruritus, burning, and stinging) on instillation. 
Less common adverse events include blurred vision, sticky 
eye sensation, and foreign body sensation on instillation. To 
the best of our knowledge, no in vitro studies on the toxicity 
of an azithromycin ophthalmic solution on corneal epithelial 
cells has been reported. However, Wingard et al performed 
an azithromycin toxicity assay on corneal epithelial cells 
as part of an extensive study designed to investigate the 
ability of some antibiotics to protect mammalian cells from 
destruction by bacteria, and showed that azithromycin had 
low in vitro toxicity.17
The aim of this in vitro study was to evaluate the cyto-
toxic effects of a commercially available azithromycin 1.5% 
ophthalmic solution on rabbit corneal epithelial cells and to 
compare these effects with those of other commonly used anti-
biotic eye drops. Benzalkonium chloride (BAK) was used as 
positive control. BAK is a quaternary ammonium compound 
used as a preservative in over 70% of the existing multi-dose 
ophthalmic solution bottles, at an average concentration of 
0.01%. BAK is known to promote activation of lipoxygenases 
and the synthesis and secretion of eicosanoids, inflammatory 
mediators, and many cytokines such as interleukin (IL)-1α, 
IL-8, IL-10, and tumor necrosis factor-alpha, resulting in 
delayed hypersensitivity and allergic reactions.18
Three mechanisms of BAK toxicity have been described: 
(1) a detergent effect causing loss of tear-film stability, 
(2) direct damage to the corneal and conjunctival epithelium, 
and (3) an immunoallergic reaction. It acts by denaturing 
proteins and disrupting cytoplasmic membranes.18
Materials and methods
Incubation with drugs
Statens Serum Institut rabbit corneal (SIRC) cells were 
purchased from Sigma-Aldrich (St Louis, MO, USA). 
Cells were resuspended and seeded into 24-well plates 
Figure 1 Phase-contrast micrographs of untreated (control) and benzalkonium 
chloride (BAK)-treated cultured rabbit corneal epithelial cells. 
Notes: Control cultures display normal cell morphology with long processes, 
no cytoplasmatic granularity, and multiple intracellular contacts. Incubation with 
BAK (0.005%–0.010%) for 15 minutes resulted in a dose-dependent cytotoxicity; 
cells show “rounding” of the cell bodies, thickening of cellular processes, and 
vacuolization of the cytoplasm (arrows). Incubation with azithromycin 1.5% (Azyter; 
Laboratoires Théa, Clermont-Ferrand, France), Miglyol® (Laboratoires Théa), 
netilmicin 0.3% (nettacin®; Società Industria Farmaceutica Italiana, Catania, Italy) 
or levofloxacin 0.3% (Oftaquix; Bausch and Lomb, Milan, Italy) (containing no BAK) 
resulted in negligible signs of toxicity, in a manner that was similar to what was 
observed in control cultures treated with saline.
NaCl 0.09%
Miglyol Nettacin
Oftaquix 0.01% BAK
30 µm30 µm
30 µm30 µm
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phase-contrast microscope (Olympus IX-50; Olympus 
Europa Holding GmbH, Hamburg, Germany). Morphologic 
criteria indicating  cytotoxic drug effects – “rounding” of 
cells, loss of processes, increased granularity, isolation of 
cells, vacuolization, and cell  detachment – were assessed 
semiquantitatively according to criteria originally described 
by Seitz et al,19 with some modifications: cellular morphol-
ogy (normal, 0; slight alterations, +; altered, ++), cellular 
boundaries (not recognizable, 0; mixed shapes, +; good 
definition, ++), nucleus and cytoplasm (normal, 0; slight 
alterations, +; altered, ++), nuclear morphology (well-spread 
chromatin, 0; mixed shapes, +; altered [pycnosis, cariorexis, 
etc], ++), and vacuolization (absent, 0; rare vacuoles, +; 
vacuolization present, ++).
Lactate dehydrogenase (LDH) assay
Cell damage in SIRC cells was quantitatively evaluated by 
measuring the amount of the soluble cytosolic enzyme LDH 
released from injured cells into the extracellular fluid imme-
diately or 24 hours after exposure to drugs, as previously 
described for neurons20 or corneal fibroblasts.21
The LDH level corresponding to complete cell death was 
determined for each experiment by assaying sister cultures 
exposed to BAK (0.0025%–0.0100%) for the same incuba-
tion period used for experimental drugs. Background LDH 
release was determined in control cultures not exposed to 
drugs and was subtracted from all experimental values. 
The resulting values correlated linearly with the degree 
of cell loss estimated by observation of cultures under 
phase-contrast optics or under bright-field optics following 
5 minutes incubation with 0.4% trypan blue, which stains 
debris and nonviable cells. All experiments were carried 
out in triplicate. The activity of LDH was quantified using a 
Cytotoxicity Detection Kit (LDH) from Roche Diagnostics 
(Basel, Switzerland).
Analysis of corneal wound healing
SIRC cell cultures were wounded using a small scalpel in 
24-well culture plates.22 The injured SIRC cell cultures were 
incubated with Azyter, Miglyol, NaCl, or BAK for 24 or 
48 hours. Three different experiments (n = 6 per group) were 
undertaken. The extent of healing was evaluated qualitatively 
in a blind fashion and photographed by an inverted phase-
contrast microscope (Olympus IX-50) at 0 and 48 hours. 
To quantify wound areas, they were identified and encom-
passed in a frame using Image-Pro Plus morphometric analy-
sis software (version 5.0 Media Cybernetics, Rockville, MD, 
USA) and the extent of healing was evaluated quantitatively by 
Table 1 Assessment of severity of morphologic criteria
[c] active  
principle
[c] BAK 15 minutes 6 hours
Control 0 0 0 0
Azytera 1.5% 0 0 0
Miglyol®b 0 0 0 0
nettacin®c 0.3% 0 0 0
Oftaquixd 0.3% 0 0 0
BAK 0 0.0025% 0 +
BAK 0 0.005% + ++
BAK 0 0.01% ++ +++
Notes: Using phase-contrast microscopy, severity of morphologic criteria (“rounding” 
of cells, loss of processes, cytoplasmic granularity, and isolation and detachment of 
cells) were assessed semiquantitatively: 0, none (ie, spindle-shaped cells, multiple long 
delicate processes, no cytoplasmic granularity, multiple intercellular contacts); +, mild 
(ie, spindle-shaped cells, short thickened processes in less than one-third of the cells, 
cytoplasmic granules detectable in less than one-third of the cells, reduced intercellular 
contacts); ++, moderate (ie, triangular- or polygonal-shaped cells, short thickened 
processes in more than one-third of the cells, cytoplasmic granules in more than 
one-third of cells, few intercellular contacts, moderate cell detachment); +++, severe 
(ie, round cells, no processes, no cell contact, severe cell detachment). aAzithromycin 
1.5% (Azyter; Laboratoires Théa, Clermont-Ferrand, France); bLaboratoires Théa; 
cnetilmicin 0.3% (nettacin®; Società Industria Farmaceutica Italiana, Catania, Italy); 
dlevofloxacin 0.3% (Oftaquix; Bausch and Lomb, Milan, Italy).
Abbreviation: BAK, benzalkonium chloride; [c], concentration.
(approximately 4 × 10-4 cells/cm2) using a medium containing 
90% Eagle’s minimal essential medium, 10% heat-inactivated 
fetal bovine serum, and 1 mmol/L glutamine. When they 
reached approximately 70%–80% confluence, the culture 
medium was removed and cells were exposed to one of the 
following preservative-free commercially available ophthal-
mic preparations: azithromycin 1.5% (Azyter; Laboratoires 
Théa, Clermont-Ferrand, France); caprylic/capric acid trig-
lyceride (Miglyol®, Laboratoires Théa), a vehicle of Azyter, 
a medium-chain-length triglyceride of saturated fatty acids 
(Laboratoires Théa); netilmicin 0.3% (Nettacin®, Società 
Industria Farmaceutica Italiana, Catania, Italy); and levo-
floxacin 0.3% (Oftaquix, Bausch and Lomb, Milan, Italy). 
Three different concentrations of BAK (0.0025%, 0.0050%, 
and 0.0100%) were used as toxicity controls, whereas 0.9% 
NaCl was used as negative control. Moreover, azithromycin 
solution (the active principle of Azyter) was applied in five 
different concentrations ranging from 0.5% to 2.5%.
SIRC cells were incubated with drugs according to three 
different protocols: (1) short-term (ie, 15 minutes) exposure, 
(2) short-term exposure followed by the addition of drug-free 
medium for a 24-hour recovery period, and (3) long-term 
(ie, 6 hours) exposure.
Phase-contrast microscopy
After incubation with drugs according to the three experi-
mental protocols, the SIRC cells were evaluated qualita-
tively in a blind fashion and photographed by an inverted 
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Figure 3 Evaluation of lactate dehydrogenase (LDH) release in Statens Serum Institut rabbit corneal (SIRC) cell cultures after (A) 15 minutes or (B) 6 hours of incubation 
with azithromycin 0.5%–2.5%. (C) Evaluation of LDH release in SIRC cultures 24 hours after 15 minutes incubation with all different concentrations of azithromycin.
Notes: Data are expressed as percentage of the maximal degree of cell death (incubation of cells for 6 hours with 0.01% of benzalkonium chloride [BAK]); they represent the 
mean ± standard error of the mean of at least three experiments performed in triplicate. Statistical analysis was performed using a one-way analysis of variance and Dunnett’s 
post-hoc test (*P # 0.05 vs control [crl]; **P # 0.01 vs crl).
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Figure 2 Evaluation of lactate dehydrogenase (LDH) release in Statens Serum Institut rabbit corneal (SIRC) cell cultures after (A) 15 minutes or (B) 6 hours of incubation with 
commercially available ophthalmic preparations of azithromycin (Azyter; Laboratoires Théa, Clermont-Ferrand, France), netilmicin (nettacin®; Società Industria Farmaceutica 
Italiana, Catania, Italy), and levofloxacin (Oftaquix; Bausch and Lomb, Milan, Italy) and benzalkonium chloride (BAK; 0.0025%–0.0100%). (C) Evaluation of LDH release in SIRC 
cell cultures 24 hours after 15 minutes of incubation with all compounds.
Notes: Data are expressed as percentage of the maximal degree of cell death (incubation of cells for 6 hours with 0.01% of BAK); they represent the mean ± standard 
error of the mean of at least three experiments performed in triplicate. Statistical analysis was performed using a one-way analysis of variance and Dunnett’s post-hoc test 
(*P # 0.05 vs control [crl]; **P # 0.01 vs crl).
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determining the ratio of the difference between the wound 
areas at time 0 and remaining wound areas after 48 hours.
Statistical analysis
Data are presented here as mean ± standard error of the 
mean of n experiments. The statistical significance of 
differences for the results displayed in Figures 2–5, and 
7 was analyzed using a one-way analysis of variance and 
Dunnett’s post-hoc test. A P value of 0.05 was considered 
significant. All statistical calculations were performed 
using GraphPad Prism (v 4; GraphPad Software, San 
Diego, CA, USA).
Results
Phase-contrast microscopy
SIRC cell cultures examined by phase-contrast microscopy 
following their incubation with Azyter, Miglyol, Nettacin, 
or Oftaquix demonstrated a pattern of cell toxicity that was 
negligible and comparable to that observed in control cultures 
(Figure 1 and Table 1).
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In contrast, the addition of BAK to the incubation 
medium resulted in a time- and dose-dependent increase in 
the appearance of cytotoxicity signs, including rounding of 
the cell bodies, loss of processes, and vacuolization of the 
cytoplasm, which eventually led to cell detachment and death 
(Figure 1 and Table 1).
LDH assay
Using LDH as a quantitative cytotoxicity index, we exam-
ined the extent of SIRC cell death (Figure 2). The maximal 
degree of cell death was produced in our culture system by 
incubation for 6 hours with 0.01% BAK, which produced 
a release of LDH (115 units/L) that was approximately 
threefold higher than the basal levels detected at the same 
time point (32 units/L) (Figure 2B). Incubation with 0.01% 
BAK for only 15 minutes produced a similar increase in 
LDH release (105 units/L) that was sixfold higher than the 
basal levels at the same time point (16 units/L) (Figure 2A). 
Incubation with 0.0025%–0.0050% BAK evoked a similar 
time-dependent but less pronounced increase in the release 
of LDH from SIRC cell cultures (Figure 2).
After 15 minutes of incubation, all compounds displayed 
negligible SIRC cell death (Figure 2A). A similar pattern 
supporting the nontoxic effects of Azyter and Miglyol was 
observed after 6 hours (Figure 2B). To examine whether 
these compounds could exert their toxic effects at more 
distant time intervals following exposure, we exposed 
SIRC cell cultures to all compounds for 15 minutes and 
measured LDH release 24 hours later (Figure 2C). Our 
results showed that Azyter was devoid of toxicity even when 
cell death was assessed at 24 hours after its application to 
SIRC cell cultures.
Finally, we tested different concentrations of azithro-
mycin (0.5%–2.5%) according to our three different 
protocols (Figure 3). Azithromycin displayed no signs of 
toxicity at concentrations below 2.0% but displayed signs 
of toxicity at 2.0% and 2.5% that were comparable to those 
displayed by BAK 0.005% (after 15 minutes of exposure) or 
0.01% (after 6 hours of exposure).
Corneal wound healing
In control SIRC cell cultures (NaCl 0.9%), analysis of the 
corneal wound surface revealed that the wound was almost 
completely covered and repaired after 48 hours (87.5%). Treat-
ment with Azyter or Miglyol for 48 hours somewhat reduced 
wound healing (47.3% and 25.6%, respectively), whereas 
incubation with 0.01% BAK for 48 hours severely inhibited 
epithelial wound healing (-36%) (Figures 4 and 5).
Discussion
While the safety of azithromycin ophthalmic solutions has 
been largely studied in vivo in rabbits, to our knowledge, this 
is the first in vitro study on the toxicity of an azithromycin 
ophthalmic solution in corneal epithelial cells. The aim of our 
study was to evaluate the cytotoxic effects of a commercially 
available azithromycin 1.5% ophthalmic solution in rabbit 
corneal epithelial cells and to compare these with those of 
other commonly used antibiotic eye drops.
Figure 4 Phase-contrast micrographs of wounded cultured Statens Serum Institut 
rabbit corneal (SIRC) cells. 
Notes: Left column shows the SIRC cells as wounded by a small scalpel in a culture 
dish. The wound of the control (top right) was healed after 48 hours. In cultures 
treated with azithromycin 1.5% (Azyter; Laboratoires Théa, Clermont-Ferrand, 
France) or Miglyol® (Laboratoires Théa) (middle right) for 48 hours, the wound 
surface was somewhat reduced. Incubation with 0.01% benzalkonium chloride 
(BAK) for 48 hours severely delayed epithelial wound healing.
NaCl 0.09% NaCl 0.9% 48 h
Miglyol Miglyol 48 h
 BAK 0.01%  BAK 0.01% 48 h
30 µm 30 µm
30 µm 30 µm
30 µm 30 µm
30 µm 30 µm
Azyter Azyter 48 h
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Figure 5 The wound-healing rates in Statens Serum Institut rabbit corneal (SIRC) 
cells incubated with different agents.
Notes: Data are expressed as percentage of healing at 48 hours as compared with 
wound at time 0 (100%) and represent the mean ± standard error of the mean of 
at least three different experiments performed in quadruplicate. Statistical analysis 
was performed using a one-way analysis of variance and Dunnett’s post-hoc test 
(*P # 0.05 vs [crl]; **P # 0.01 vs crl).
Abbreviation: BAK, benzalkonium chloride.
−50
−25
0
25
**
*
*
W
o
u
n
d
 h
ea
lin
g
 (
%
)
50
75
100
125
Crl
Azyter
Miglyol
BAK 0.01%
The current literature supports the efficacy and safety of 
topical azithromycin ophthalmic 1.5% solution in the treat-
ment of various ocular surface disorders, namely  bacterial 
conjunctivitis, blepharitis, and dry eye.  Azithromycin has 
been shown to be efficacious against the most common bacte-
rial pathogens of infective conjunctivitis (ie,  Staphylococcus 
aureus, Haemophilus influenzae, Streptococcus pneumo-
niae)23 and is indicated for the treatment of bacterial conjunc-
tivitis, with the recommended dosing regimen being one drop 
in the affected eye twice daily (8–12 hours apart) for the first 
2 days, then one drop once daily for the next 5 days.
The combination of anti-inflammatory properties along 
with high and prolonged tissue concentrations, particu-
larly in the lid margin and ocular surface, suggests that an 
azithromycin ophthalmic solution may serve as a treatment 
option for patients experiencing a wide range of conditions 
associated with the lid margin and ocular surface.1 The 
treatment of trachoma with topical azithromycin in addition 
to an oral dose is also encouraging.14
In the present study, we incubated corneal epithelial cells 
for 15 minutes or 6 hours with preservative-free netilmicin 
or levofloxacin and different concentrations of unpreserved 
azithromycin. Qualitative analysis was undertaken using 
phase-contrast optics and examination of the morphologi-
cal aspects of the cell cultures. Quantitative analysis was 
performed by measuring the release of cytoplasmic enzyme 
LDH into the medium immediately and 24 hours after expo-
sure to the study drugs. We also studied the wound-healing 
rates of mechanically injured corneal epithelial cells cultured 
for 48 hours. According to our results, unpreserved prepara-
tion of azithromycin up to a concentration of 1.5% showed a 
low cell toxicity, which was not significantly different from 
the other antibiotic preparations (P . 0.05), representa-
tive of the major antibiotic families of aminoglycosides 
and fluoroquinolones and available in preservative-free 
formulations.
Moreover, azithromycin did not inhibit the wound-heal-
ing process after the mechanical injury. The unpreserved 
preparation of azithromycin was virtually devoid of harmful 
effects under our experimental conditions, up to a concen-
tration of 1.5% and also showed good recovery properties 
after a mechanical wound test. In control SIRC cell cultures 
(NaCl 0.9%), qualitative analysis of the corneal wound sur-
face demonstrated that the wound was almost completely 
covered and repaired after 48 hours. Treatment with Azyter 
or Miglyol for 48 hours slightly reduced cell wound heal-
ing, whereas incubation with 0.01% BAK for 48 hours 
severely delayed epithelial wound healing. This evidence 
supports our hypothesis concerning the cytotoxic role of 
preservatives in commercial preparations of eye drops 
and the relative non-toxicity of mono-dose unpreserved 
antibiotics already demonstrated by a previous study.24 The 
low toxic effects of azithromycin may work synergistically 
with the previously described anti-inflammatory effects on 
the ocular surface.
Conclusion
This cell-culture study provides remarkable information 
about the in vitro toxicity profile of an unpreserved 1.5% 
azithromycin ophthalmic solution. Even though this study has 
the limitations of an in vitro analysis, the available clinical 
data on tolerability appear in line with our results.
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